Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up
Connect Twitter with Market Wire News

GBT News and Press, Global Blood Therapeutics Inc.


home / stock / gbt / gbt news

RSS
  • Global Blood, Impel Pharma could be M&A targets after Biohaven deal - analysts

    Global Blood Therapeutics (NASDAQ:GBT) may be a potential acquisition candidate in the biotech space following Pfizer (PFE)'s deal to acquire Biohaven Pharmaceutical for about $11.6 billion, according to a Wedbush analyst. "In light of Pfizer’s $12 billion acquisition of Biohaven Pharm...

    • May 15, 2022 09:00:00 am
    • |
    • SeekingAlpha
    • |
      • GBT Stock
      • GBT Quote
      • GBT Short
      • GBT News
      • GBT Articles
      • GBT Message Board
  • GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress

    New real-world evidence data on Oxbryta ® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASD...

    • May 12, 2022 10:00:00 am
    • |
    • GlobeNewswire
    • |
      • GBT Stock
      • GBT Quote
      • GBT Short
      • GBT News
      • GBT Articles
      • GBT Message Board
  • Why Global Blood Therapeutics Stock Was Sickly Today

    After market hours on Wednesday, Global Blood Therapeutics (NASDAQ: GBT) released a first-quarter earnings report that investors didn't digest well. As a result, the following day, the stock fell by 8% -- a steep rate, even on a very bearish day when the S&P 500 index declin...

    • May 05, 2022 06:40:00 pm
    • |
    • Motley Fool
    • |
      • GBT Stock
      • GBT Quote
      • GBT Short
      • GBT News
      • GBT Articles
      • GBT Message Board
  • Global Blood Therapeutics (GBT) Q1 2022 Earnings Call Transcript

    Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q1 2022 Earnings Call May 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q1 2022 Earnings Call Transcript ...

    • May 04, 2022 11:30:34 pm
    • |
    • Motley Fool
    • |
      • GBT Stock
      • GBT Quote
      • GBT Short
      • GBT News
      • GBT Articles
      • GBT Message Board
  • Global Blood Therapeutics Inc. (GBT) CEO Ted Love on Q1 2022 Results - Earnings Call Transcript

    Global Blood Therapeutics, Inc. (GBT) Q1 2022 Earnings Conference Call May 04, 2022 4:30 PM ET Company Participants Steven Immergut – Senior Vice Preside, Head-Corporate Communications and Investor Relations Ted Love – President and Chief Executive Officer Jeff Farrow – C...

    • May 04, 2022 10:39:04 pm
    • |
    • SeekingAlpha
    • |
      • GBT Stock
      • GBT Quote
      • GBT Short
      • GBT News
      • GBT Articles
      • GBT Message Board
  • Global Blood Therapeutics GAAP EPS of -$1.26 beats by $0.06, revenue of $55.16M misses by $0.97M

    Global Blood Therapeutics press release (NASDAQ:GBT): Q1 GAAP EPS of -$1.26 beats by $0.06. Revenue of $55.16M (+41.3% Y/Y) misses by $0.97M. For further details see: Global Blood Therapeutics GAAP EPS of -$1.26 beats by $0.06, revenue of $55.16M misses by $0.97M

    • May 04, 2022 04:16:14 pm
    • |
    • SeekingAlpha
    • |
      • GBT Stock
      • GBT Quote
      • GBT Short
      • GBT News
      • GBT Articles
      • GBT Message Board
  • GBT Reports First Quarter 2022 Financial Results

    Achieved Oxbryta ® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year Strong new prescription growth driven by the recent launch for children ages 4 to less than 12 years and improving trends for patients ages 12 y...

    • May 04, 2022 04:05:00 pm
    • |
    • GlobeNewswire
    • |
      • GBT Stock
      • GBT Quote
      • GBT Short
      • GBT News
      • GBT Articles
      • GBT Message Board
  • Global Blood Therapeutics Q1 2022 Earnings Preview

    Global Blood Therapeutics (NASDAQ:GBT) is scheduled to announce Q1 earnings results on Wednesday, May 4th, after market close. The consensus EPS Estimate is -$1.36 and the consensus Revenue Estimate is $56.13M (+43.8% Y/Y). Over the last 1 year, GBT has beaten EPS estimates 25% of the time an...

    • May 03, 2022 05:45:56 pm
    • |
    • SeekingAlpha
    • |
      • GBT Stock
      • GBT Quote
      • GBT Short
      • GBT News
      • GBT Articles
      • GBT Message Board
  • GBT Launches Inaugural Environmental, Social and Governance (ESG) Report

    SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to meeting the needs of underserved patient communities starting with sickle cell disease (SCD), today released its inaugural environm...

    • April 28, 2022 08:20:32 am
    • |
    • GlobeNewswire
    • |
      • GBT Stock
      • GBT Quote
      • GBT Short
      • GBT News
      • GBT Articles
      • GBT Message Board
  • GBT to Announce First Quarter 2022 Financial Results on Wednesday, May 4, 2022

    SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after U.S. financial markets close. Management will host a con...

    • April 27, 2022 08:00:00 am
    • |
    • GlobeNewswire
    • |
      • GBT Stock
      • GBT Quote
      • GBT Short
      • GBT News
      • GBT Articles
      • GBT Message Board
Next 10
Stock Information

Global Blood Therapeutics Inc. Company Name:

GBT Stock Symbol:

NASDAQ Market:

MENU
GBT GBT Quote GBT Short GBT News GBT Articles GBT Message Board
Get GBT Alerts

News, Short Squeeze, Breakout and More Instantly...

Connect Twitter with Market Wire News
RECENT GBT NEWS
  • GBT - GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress

    New real-world evidence data on Oxbryta ® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASD...

  • GBT - Why Global Blood Therapeutics Stock Was Sickly Today

    After market hours on Wednesday, Global Blood Therapeutics (NASDAQ: GBT) released a first-quarter earnings report that investors didn't digest well. As a result, the following day, the stock fell by 8% -- a steep rate, even on a very bearish day when the S&P 500 index declin...

  • GBT - Global Blood Therapeutics (GBT) Q1 2022 Earnings Call Transcript

    Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q1 2022 Earnings Call May 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q1 2022 Earnings Call Transcript ...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Join us on Discord

Join us on Discord

Follow us on discord to get immediate notifications!

Check out the New Market Wire News Discord Bot

Discord


Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email [email protected].

WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected
Follow @MarketWN

Contact

Privacy

Terms of Service

Disclaimer

© 2020 Market Wire News